

Review

Open Access

Immune defects in Alzheimer's disease: new medications development

John R Cashman*¹, Senait Ghirmai¹, Kenneth J Abel¹ and Milan Fiala²

Address: ¹Human BioMolecular Research Institute, San Diego, CA 92121, USA and ²Department of Medicine, Greater Los Angeles Veteran's Affairs Medical Center, Los Angeles, CA 90095, USA

Email: John R Cashman* - JCashman@HBRI.org; Senait Ghirmai - SGhirmai@HBRI.org; Kenneth J Abel - KAbel@HBRI.org; Milan Fiala - Fiala@mednet.ucla.edu

* Corresponding author

from 8th International Conference on Alzheimer's Disease Drug Discovery
New York, NY, USA. 15–16 October 2007

Published: 3 December 2008

BMC Neuroscience 2008, 9(Suppl 2):S13 doi:10.1186/1471-2202-9-S2-S13

This article is available from: <http://www.biomedcentral.com/1471-2202/9/S2/S13>

© 2008 Cashman et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease characterized by the accumulation of intracellular and extracellular aggregates. According to the amyloid beta (A β) hypothesis, amyloidosis occurring in the brain is a leading cause of neurodegeneration in AD. Defects in the innate immune system may decrease the clearance of A β in the brain. Macrophages of most AD patients do not transport A β into endosomes and lysosomes, and monocytes from AD patients do not efficiently clear A β from AD brain. After stimulation with A β , mononuclear cells of normal subjects display up-regulated transcription of *MGAT3*, which encodes β -1,4-mannosyl-glycoprotein 4- β -N-acetylglucosaminyltransferase, and *Toll-like receptor (TLR)* genes. Monocytes of AD patients generally down-regulate these genes. A commonly used, naturally occurring material from a spice that enhances certain key functions defective in cells of innate immunity of many AD patients has shown epidemiologic rationale for use in AD treatment. Bisdemethoxycurcumin, a natural curcumin, is a minor constituent of turmeric (curry), and it enhances phagocytosis and clearance of A β in cells from most AD patients. We confirmed the effectiveness of a synthetic version of the same compound. In mononuclear cells of most AD patients, bisdemethoxycurcumin enhanced defective phagocytosis of A β and increased the transcription of *MGAT3* and *TLR* genes. The potency of bisdemethoxycurcumin as a highly purified compound in facilitating the clearance of A β in mononuclear cells suggests the promise of enhanced effectiveness compared to curcuminoid mixtures. Bisdemethoxycurcumin appears to enhance immune function in mononuclear cells of AD patients and may provide a novel approach to AD immunotherapy.

Background

Alzheimer's disease (AD) is a major public health problem with a huge associated impact on individuals, families, the healthcare system, and society. It is estimated that

as many as five million Americans currently suffer from AD, and 50% of people over the age of 85 may have AD. By the year 2050, the number of affected individuals in the United States is expected to increase to over 13 million

[1]. In Europe and other countries, where the number of newborns is decreasing, the number of AD patients is expected to increase dramatically as the population ages [2]. AD is a heavy economic burden on individuals and society, with an estimated annual cost of \$100 billion in the US alone. Current therapeutics show only limited effectiveness in ameliorating the symptoms of AD and in improving cognitive ability. Developing an effective therapeutic to combat AD is therefore an immediate and important challenge. Immune-based approaches to treat Alzheimer's disease have shown some promise [3]. However, when applied to humans, immunization with amyloid beta ($A\beta$) resulted in development of adverse inflammatory responses in a small fraction of the patients tested [4]. Other small molecule immunostimulatory-based strategies may be beneficial. Studies of natural compounds that improve certain defects in innate immune cells of some AD patients suggest a novel and safe therapeutic approach. For example, the natural product mixture curcuminoids selectively enhanced $A\beta$ phagocytosis and gene transcription in blood cells of AD patients [5]. Characterization of the immunostimulatory properties, and the different cellular and gene responses to curcumin, may help to explain observed differences in $A\beta$ phagocytic response between AD and normal individuals, and may eventually lead to diagnostic testing for disease susceptibility or drug response.

Treatment of Alzheimer's disease

Treatment of AD remains a challenging goal due to our incomplete understanding of its pathogenesis. AD is a multi-component disease, and many biological and physiological steps are involved in the eventual pathological condition. Among other symptoms, the disease is associated with accumulation of neurofibrillary tangles and amyloid plaques in brain tissue of affected individuals. According to the ' $A\beta$ hypothesis', the accumulation of abnormally folded amyloid protein in the brain of AD patients is a leading cause of neurodegeneration [6]. The presence of excess $A\beta$ may be a consequence of two possible pathways: an abnormal and toxic accumulation of $A\beta$; and a defective detoxification mechanism that would ordinarily clear accumulating $A\beta$. The mechanisms of neurodegeneration resulting from abnormally folded proteins such as $A\beta$ remain poorly understood. With an increasingly aging population, there exists an urgent need for new and more effective therapeutic approaches [7].

Considerable interest exists in the role that the immune system plays in AD pathology. Macrophages and microglia are the innate immune cells responsible for clearance of pathogens and waste products. It has been shown that peripheral blood mononuclear cells (PBMCs) and macrophages of AD patients cross the blood-brain barrier, but are defective in clearance of $A\beta$ in neuritic plaques, and

over-express cyclooxygenase-2 and inducible nitric oxide synthase [8]. Resident microglia in AD brain display markers of phagocytic and inflammatory, but not pro-phagocytic, genes [9]. However, in a transgenic mouse model of AD, most microglia invading $A\beta$ plaques are bone marrow-derived, not resident microglia [10]. Thus, the brains of AD patients and transgenic mice appear to display microglial inflammatory responses, together with defective $A\beta$ clearance by blood-borne macrophages. Defects in the innate immune system of AD patients may therefore play a significant role in brain amyloidosis leading to brain inflammation and neurodegeneration. Enhancement of a patient's innate immunity might represent a novel approach to AD therapy.

In addition to defects in both $A\beta$ phagocytosis and clearance of $A\beta$ in AD brain sections, several molecular markers for monocytes and macrophages have been associated with AD [11]. Unlike PBMCs from AD patients, PBMCs from control subjects were found to up-regulate a number of genes, including, among others, *MGAT3* (β -1,4-mannosyl-glycoprotein-4- β -N-acetylglucosaminyltransferase), and Toll-like receptor (*TLR*) genes, which are crucial for macrophage function. Evidence for a role of mutated *MGAT3* in transgenic mouse neuropathology has been published [12], and we have reported suggestive evidence for a correlation between defective *MGAT3* expression and deficient $A\beta$ phagocytosis [11]. Microarray expression studies also identified several genes significantly up-regulated in AD relative to control PBMCs in response to $A\beta$ exposure [11]. What is not clear from these studies is whether normal expression of these genes is necessary and sufficient for efficient $A\beta$ clearance, or whether other genes and pathways are involved. Also, given previous observations that macrophage $A\beta$ phagocytosis is not defective in all AD patients [5], it is unknown to what extent naturally occurring polymorphisms in these important genes may account for differences in $A\beta$ uptake between individuals. In this context, AD pathogenesis may also involve other polymorphic proteins, including amyloid precursor protein (APP), apolipoprotein E, and other proteins in cellular mechanisms, including APP processing [13], oxidative stress [14,15], and neuronal apoptosis [16-18]. Clearly, a better understanding of the genes responding to $A\beta$ accumulation, and their involvement in $A\beta$ phagocytosis and clearance is needed.

Curcumins as AD therapeutics

Our studies have led us to examine the family of natural products, curcumins, present in significant concentrations in the spices turmeric and red curry, for which there exists epidemiologic and aging-related rationale for use in AD treatment [11]. There is evidence that consumption of these natural compounds in various Asian populations is associated with a protective effect against AD [19]. Also,

curcumin has been shown to enhance brain clearance of A β in mouse models of AD [20]. However, curcuminoid mixtures are composed of at least three curcumin compounds. The three most prominent members of this class of natural product include curcumin, demethoxycurcumin and bisdemethoxycurcumin (Figure 1). Curcumin is the major material present in curcuminoids, and demethoxycurcumin and bisdemethoxycurcumin are minor constituents. A commonly observed ratio of curcumin:demethoxycurcumin:bisemethoxycurcumin in commercially available curcuminoid mixtures is 66:23:11. As described above, the curcuminoid mixture was shown to possess significant immune-stimulating properties. Based on commonly observed biological activities of natural products, we expected the curcuminoid mixture to contain one compound that was more potent than other materials present. We hypothesized that purification of the most biologically potent material could offer a potential drug discovery path for a new therapeutic approach. We conducted a bio-directed purification of the active component and showed that fractions enriched in bisdemethoxycurcumin could improve the deficits in A β uptake and clearance by innate immune cells from AD patients (Figure 1) [11]. Bio-directed purification and isolation of the most potent curcumin involved chemical extraction and chromatographic purification, resulting in increasingly pure compounds until the biological activity was associated with one highly purified fraction. This material was quite pure and liquid chromatography-mass spectrometry showed that it was largely bisdemethoxycurcumin. Bisdemethoxycurcumin was examined for its ability to stimulate phagocytosis of A β in cells from control and AD patients. Compared to the curcuminoid mixture, and other curcumin components, bisdemethoxycurcumin was the most potent compound at stimulating phagocytosis of A β . The enhanced phagocytosis capabilities in the presence of bisdemethoxycurcumin was also generally associated with increases in expression of *MGAT3* and *TLR* genes in PBMCs from individuals testing positive for AD. Based on mass spectrometric analysis that identified bisdemethoxycurcumin as the most immuno-stimulatory constituent in curcuminoid fractions, we verified the immuno-enhancing effects of bisdemethoxycurcumin by chemically synthesizing the same material and retesting it alongside other highly purified synthetic and natural curcumins. In all cases examined, bisdemethoxycurcumin showed the most potent immuno-stimulatory activity compared with other synthetic or natural curcumins or demethoxycurcumin. Thus, these studies identified a naturally occurring compound with the potential of at least partially correcting cellular deficits associated with phagocytosis of A β of relevance to AD. Because bisdemethoxycurcumin has been used safely (albeit in a mixture of other curcuminoids) for thousands of years, it is possible that it may be directly useful as an agent to treat AD. How-




Figure 1

Chemical structures of the principal constituents of curcuminoid. Shown are the three predominant curcuminoids found in natural mixtures. Curcumin is commonly observed to be the major material, whereas demethoxycurcumin and bisdemethoxycurcumin are relatively minor constituents.

ever, safety studies may be required before the purified compound is administered to humans. Regardless of the advantages and disadvantages of bisdemethoxycurcumin as an anti-AD agent, it can provide a lead molecule for the elaboration of other compounds to be tested as immuno-stimulating agents. The relative ease in synthesizing a variety of derivatives based on the bisdemethoxycurcumin structure allows us to address whether close structural analogs may afford more drug-like compounds and provide enhanced effectiveness and more promising drug candidates.

Extracts containing curcuminoids are currently in clinical use for a number of applications, including treatment of

colon and pancreatic cancers, multiple myeloma, AD, and ulcerative colitis [21,22]. Curcuminoid extracts are also available over-the-counter as herbal supplements. Relatively large doses of curcuminoids are being used (that is, 2–8 g/day) because of limited bioavailability. Low bioavailability is likely the result of rapid metabolism and low gut penetration into the bloodstream. For example, curcuminoids compete for conjugation metabolic pathways [23,24], oxidative metabolic pathways [25], and intestinal efflux [26]. To improve clinical utility, and enhance bioavailability, combination formulations involving the use of agents that compete with metabolism and efflux mechanisms likely will be required to increase blood levels of curcuminoids. Regardless, the apparent interaction with oxidative and conjugative metabolic pathways suggests that herb-drug interactions could pose a problem. The approach to identify the most potent constituent in the curcuminoid mixture could circumvent a number of the bioavailability issues if the prominent curcumin components are responsible for drug metabolism shortcomings.

Defective phagocytosis of A β in AD

AD amyloidosis may be related to defective brain clearance of A β by monocytes and macrophages and differences in gene transcription [5]. As described before [11], macrophages of most AD patients do not efficiently transport A β into endosomes and lysosomes, and AD patient monocytes do not efficiently clear A β from the AD brain *in vitro* and *in vivo*, although they retain the ability to phagocytose bacterial pathogens, for example, *Escherichia coli* and *Staphylococcus aureus*. In contrast, macrophages of normal subjects efficiently transport A β to endosomes and lysosomes, and control monocytes clear A β in AD brain sections. As described more fully in a later section, treating PBMCs from control subjects with A β was associated with a relatively elevated expression of the gene *MGAT3*, and genes encoding TLRs. In contrast, and in general, monocytes from AD patients markedly down-regulate these same genes with the same treatment. These levels of expression may correlate with the cells' ability to take up and degrade A β , and experimental inhibition of *MGAT3* expression using small interfering RNA was shown to interfere with A β clearance [11].

Endocytosis and intracellular transport of A β in macrophages

Fluorescein isothiocyanate (FITC)-A β phagocytosis by macrophages from 42 control subjects, and 73 AD patients, showed that macrophages of control subjects usually (that is, approximately 90%) showed either excellent or extremely efficient phagocytosis of soluble FITC-A β within 24 hours. In contrast, a small fraction (15%) of macrophages from AD patients showed extremely efficient phagocytosis and the remainder displayed either minimal surface uptake of FITC-A β (60%), or strong sur-

face localization but no intracellular uptake (25%). In macrophages from control subjects, the intracellular transport of A β was rapid. After one and two hour post-exposure of macrophages from control subjects, FITC-A β co-localized with the early endosomal marker Rab5. In contrast, Rab5 staining and co-localization were minimal in macrophages from AD patients. In macrophages from control subjects, FITC-A β co-localized with the lysosomal marker Lysotracker at each time interval (that is, 1, 48, and 72 hours) post-exposure. In contrast, A β bound to the cell surface of macrophages from AD patients, but did not progress to lysosomes over a 72 hour period, and the lysosomes were poorly expressed. It appears that the mechanism involving phagocytosis of bacteria is distinct from the phagocytotic mechanism for A β .

Clearance of A β in Alzheimer brain sections by control and AD monocytes

As described previously, the phagocytic ability of monocytes to digest A β in brain tissue was tested by co-culturing human PBMCs with frozen sections of brain from patients positively identified as having AD [11]. PBMCs from AD patients and controls were co-cultured with frozen serial sections of the frontal lobes of AD patients. The brain section cultures were done under conditions that excluded the role of antibodies in the clearance of brain A β . The results were consistent: one-third of the monocytes examined from control subjects were saturated with fluorescently labeled A β after 2 days of co-culture, and 100% were saturated after co-culturing for 4 days. In contrast, less than one-quarter of the monocytes examined from AD patients became saturated with A β , and the remaining monocytes from AD patients were shrunken and aggregated into clusters with staining that suggested monocyte aggregation and A β release. The results suggested that monocytes from control individuals were markedly more effective at clearing A β when co-cultured with brain tissue than monocytes from AD patients that were defective in A β clearance [11].

Transcriptional dysregulation in PBMCs of AD patients

Whole-genome microarray analysis of mRNAs was carried out to compare expression patterns in PBMCs of AD patients and controls after overnight treatment with A β . Compared to cells from AD patients, control cells up-regulated (>2.2-fold) the transcription of 35 genes and expressed sequence tags (ESTs), including *MGAT3* (327-fold, $P < 0.001$), and the genes encoding fibronectin (*FN1*; 10.1-fold, $P < 0.001$), cholinergic receptor, muscarinic 4 (9.3-fold, $P < 0.001$), and 2'-5'-oligoadenylate synthetase 3 (*OAS*; 7.8-fold, $P < 0.001$), and down-regulated (>2-fold) the transcription of an additional 35 genes or ESTs. The most prominent transcriptional change in AD macrophages involved down-regulation of *MGAT3* transcription

upon A β stimulation. The product of the *MGAT3* gene is *N*-acetylglucosaminyltransferase III (GlcNAc-TIII), which transfers the bisecting *N*-acetylglucosamine to the core mannose of complex *N*-glycans [27,28]. Another function of GlcNAc-TIII is to stop further processing and elongation of *N*-glycans [29]. GlcNAc-TIII modulates cell interactions, and potentiates α 1 integrin-mediated neuritogenesis [30]. Animals with truncated, inactive GlcNAc-TIII show neurological dysfunction [12]. Compared to macrophages cultured from control individuals, macrophages cultured from AD patients are more susceptible to apoptosis by A β [15,31]. However, over-expression of GlcNAc-TIII has been shown to protect cells against hydrogen peroxide-induced apoptosis [32], and thus could help stabilize AD macrophages during A β phagocytosis. Transcriptional dysregulation of GlcNAc-TIII could also lead to the altered *N*-glycosylation observed in AD [11]. In the AD patients examined, the *MGAT3* gene defect was strongly associated with AD in the 60–80 years age group, but not in subjects >80 years old. Also, the observed marginal association between decreased *MGAT3* expression and deficient A β phagocytosis ($P = 0.069$) supports the idea that AD subjects >80 years old are distinct in so far as phagocytosis is concerned.

To confirm the suggested transcriptional differences observed between cells from AD patients and control subjects, *MGAT3* responses to A β in PBMCs of 18 AD patients, and 9 control subjects, were investigated using quantitative real-time PCR (qPCR) [11]. Cells from most AD patients (12/18) showed down-regulation of *MGAT3* (that is, ratio = 0.00001 to 0.99). The data were expressed as a ratio of qPCR signal for the treated versus untreated cells to account for variable baseline values between subjects. The remaining samples from six AD patients (including three AD patients >80 years old) up-regulated *MGAT3*. In contrast, with the exception of two subjects >80 years old, most samples from control individuals up-regulated *MGAT3* upon A β stimulation. Excluding the >80 year-old population samples, in which greater variation was observed, the mean log *MGAT3* RNA score of AD patients (-1.747) and that of control subjects (+3.77) differed even more significantly ($P = 0.001$). Transcriptional down-regulation in macrophages from AD patients of two other genes noted in the microarray analysis, *FN1* and *OAS*, was also confirmed by qPCR. Co-treatment with bisdemethoxycurcumin was associated with significant increases in *MGAT3* gene expression ratios in AD patient cells.

Transcription of TLR genes in mononuclear cells of AD patients and control subjects

TLRs are crucial for macrophage function, and play an important role in the detection of non-self by the innate immune system. Activation of TLRs results in many func-

tional outcomes, including enhancement of apoptosis, secretion of inflammatory cytokines, and direct antimicrobial activity [33]. Expression of TLR genes in response to A β stimulation was examined using PBMCs of AD patients and control subjects. A striking difference was observed in TLR mRNA levels between PBMCs from control individuals and AD patients stimulated with A β . Whereas control PBMCs exposed to A β up-regulated TLRs, transcription of *TLR1*, *TLR2*, *TLR3*, *TLR5*, *TLR8*, and *TLR10* was significantly down-regulated in similarly treated AD cells. It is possible that the lower expression levels of TLR genes in AD macrophages may be indicative of more global innate immune defects beyond A β phagocytosis.

Expression profiling

The microarray and qPCR expression profiling identified certain genes dysregulated in AD relative to control PBMCs in response to A β treatment. We sought to identify gene networks and biochemical pathways that may be significantly up- or down-regulated in response to A β and curcumins. Such gene pathway analyses may help identify additional targets to understand the complexity of AD as well as to find new potential targets for therapeutic intervention. We used *in silico* tools from Ingenuity <http://www.ingenuity.com> to identify pathways reportedly involving *MGAT3* that may be associated with the phagocytic and transcriptional responses dysregulated in AD patient cells. Figure 2 depicts other gene products and pathways for which interactions involving *MGAT3* in various cell types, and under various conditions, have been reported. Based on other proteins in the network, it is interesting to speculate that *MGAT3* in PBMCs may be part of signaling pathways involving integrins plus Jun- and MAP-kinases, and may contribute to leukocyte extravasation into tissues, among other biological activities. Integrating the pathway information with microarray data from differently treated cells will allow the assembly and quantification of sets of genes that appear to be significantly over-represented among all known genes, and determine if those genes are related biologically. In this way, we can determine which metabolic, biochemical, and transcriptional networks and pathways appear to be responsive to A β and curcumin treatments. An important objective of the pathway analyses will be to investigate the roles of these, and their possibly novel activities, in the context of A β phagocytosis in PBMCs. These analyses may reveal other responding genes in addition to *MGAT3* and the TLR genes, possibly suggesting other cellular targets that may be amenable to drug intervention.

Conclusion

Mononuclear cells from AD patients generally display defective phagocytosis and transcriptional down-regulation of certain key genes associated with phagocytosis. Compared with age-matched mononuclear cells from




Figure 2

Putative biochemical pathways involving *MGAT3*. Shown are pathways and gene networks with reported interactions involving *MGAT3* under various conditions. Pathway analysis was performed using IPA tools (Ingenuity). Interactions are shown by lines: lines with arrows represent direct interactions and lines without arrows indicate binding only. Solid lines show reported direct interactions and broken lines show indirect interactions. Functions are indicated by shapes: enzymes (diamonds), cytokines (squares), kinases (triangles), transcription regulators (horizontal ovals), transmembrane receptors (vertical ovals), transporters (trapezoids), complexes (concentric circles), and other (circles).

controls, cells from AD patients showed significant defects in innate immunity, including poor clearance of $A\beta$ *in vitro* and marked differences in gene transcription. After $A\beta$ stimulation of mononuclear cells from AD patients, the most prominent transcriptional defect observed involved down-regulation of *MGAT3* and TLR genes. *MGAT3* may play a pivotal role in $A\beta$ phagocytosis because silencing of its transcription inhibited $A\beta$ phagocytic function in monocytes from control individuals.

MGAT3 encodes an enzyme (GlcNAc-TIII) that modulates cell interactions on a number of levels through *N*-glycosylation of key proteins. It is possible that such an overarching enzymatic activity that is responsible for regulating a whole host of biological processes is a lynchpin in the complex process of phagocytosis. Undoubtedly, an array of coordinated events involving a large number of proteins and receptors (many of which require *N*-glycosylation for their biological activity) is required for $A\beta$

phagocytosis, and *MGAT3* appears to play a prominent role. Another gene family that is significantly down-regulated in monocytes from AD patients stimulated with A β is the *TLR* family of genes, members of which are crucial for macrophage function. TLRs are pattern recognition receptors, found on many cell types, including cells of the innate immune system, that recognize conserved pathogen associated molecular patterns. Activation of TLRs results in many functional outcomes, including enhancement of apoptosis, secretion of inflammatory cytokines and recognition of foreign materials, including bacteria. Thus, TLRs perform a number of global functions for innate cellular immunity. A defective TLR system is anticipated to have far-reaching consequences for abnormal A β phagocytosis as well as other functions in innate immunity beyond A β phagocytosis.

Our studies led us to examine the natural product curcumin, present in significant concentrations in the spices turmeric and red curry, as there is an epidemiologic and aging-related rationale for their use in AD treatment. There is evidence that consumption of these natural compounds in various Asian populations is associated with a protective effect against AD [19]. Also, curcumin has been shown to enhance brain clearance of A β in mouse models of AD [20,34]. Offering the potential for a new therapeutic approach, we identified a certain constituent of this natural compound mixture (that is, bisdemethoxycurcumin) that can improve the defects in A β uptake and clearance by the innate immune cells from AD patients [11]. Administration of bisdemethoxycurcumin to mononuclear cells from AD patients was generally associated with enhancement of A β phagocytosis and an increase in expression of *MGAT3* and *TLR* genes in most AD patients. Stimulation of mononuclear cells from control individuals with bisdemethoxycurcumin did not change A β phagocytosis nor increase expression of *MGAT3* or *TLR* genes, suggesting that the curcuminoid bisdemethoxycurcumin was selectively up-regulating key genes in cells from AD patients. We verified the effects of the immunoenhancing compound (bisdemethoxycurcumin) using a chemically synthesized version. Thus, these studies led to the identification of a natural compound with the potential of correcting cellular defects associated with AD. Synthesis of more drug-like derivatives of bisdemethoxycurcumin may allow us to address whether structural analogs could provide enhanced effectiveness and provide promising drug candidates. A more complete knowledge of the gene expression profiles in innate immune cells in response to biologically active compounds will be invaluable toward understanding the mechanisms of A β uptake, and for guiding rational drug development efforts.

List of abbreviations used

A β : amyloid-beta; AD: Alzheimer's disease; APP: amyloid precursor protein; *MGAT3*: β -1,4-mannosyl-glycoprotein 4- β -N-acetylglucosaminyltransferase; PBMC: peripheral blood mononuclear cell; TLR: Toll-like receptor.

Competing interests

A provisional US patent has been submitted by JRC and MF involving curcuminoids as therapeutics, and genetic markers associated with A β phagocytosis as useful diagnostics.

Acknowledgements

This study was supported in part by the grant from the Alzheimer's Drug Discovery Foundation (ADDF) <http://www.alzdiscovery.org> to JRC. The ADDF catalyzes and funds drug discovery and drug development for Alzheimer's disease and cognitive aging. Partial financial support was also provided to MF by a grant from the Alzheimer's Disease Association. Samples from patients and control subjects were obtained under an approval from the UCLA IRB. Informed written consent was obtained from the patients or their relatives, and from control subjects.

This article has been published as part of *BMC Neuroscience* Volume 9 Supplement 2: 2008 Proceedings of the 8th International Conference on Alzheimer's Disease Drug Discovery The full contents of the supplement are available online at <http://www.biomedcentral.com/1471-2202/9?issue=S2>.

References

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: **Alzheimer's disease in the US population: prevalence estimates using the 2000 census.** *Arch Neurol* 2003, **60**:1119-1122.
2. Wancata J, Musalek M, Alexandrowicz R, Krautgartner M: **Number of dementia sufferers in Europe between the years 2000 and 2050.** *Eur Psychiatry* 2003, **18**:306-313.
3. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang JP, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao ZM, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D: **Immunization with amyloid-beta attenuates Alzheimer's disease-like pathology in the PDAPP mouse.** *Nature* 1999, **400**:173-177.
4. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Joanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C: **Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.** *Neurology* 2003, **61**:46-54.
5. Zhang L, Fiala M, Cashman J, Sayre J, Espinosa A, Mahanian M, Zaghi J, Badmaev V, Graves MC, Bernard G, Rosenthal M: **Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients.** *J Alzheimers Dis* 2006, **10**:1-7.
6. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R: **3D structure of Alzheimer's amyloid-beta(1-42) fibrils.** *Proc Natl Acad Sci USA* 2005, **102**:17342-17347.
7. Golde TE: **The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer's disease.** *Brain Pathol* 2005, **15**:84-87.
8. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV: **Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier.** *Eur J Clin Invest* 2002, **32**:360-371.
9. Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE: **Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes.** *J Leukoc Biol* 2006, **79**:596-610.
10. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S: **Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.** *Neuron* 2006, **49**:489-502.

11. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J, Mahanian M, Baghaee A, Hong P, Cashman J: **Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin.** *Proc Natl Acad Sci USA* 2007, **104**:12849-12854.
12. Bhattacharyya R, Bhaumik M, Raju TS, Stanley P: **Truncated, inactive N-acetylglucosaminyltransferase III (GlcNAc-TIII) induces neurological and other traits absent in mice that lack GlcNAc-TIII.** *J Biol Chem* 2002, **277**:26300-26309.
13. Rogava E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, et al.: **The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease.** *Nat Genet* 2007, **39**:168-177.
14. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP: **Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.** *Proc Natl Acad Sci USA* 2004, **101**:2070-2075.
15. Mattson MP: **Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders.** *Antioxid Redox Signal* 2006, **8**:1997-2006.
16. Jordan-Sciutto K, Rhodes J, Bowser R: **Altered subcellular distribution of transcriptional regulators in response to Abeta peptide and during Alzheimer's disease.** *Mech Ageing Dev* 2001, **123**:11-20.
17. Wang Y, Xie WY, He Y, Wang M, Yang YR, Zhang Y, Yin DM, Jordan-Sciutto KL, Han JS, Wang Y: **Role of CDK5 in neuroprotection from serum deprivation by mu-opioid receptor agonist.** *Exp Neurol* 2006, **202**:313-323.
18. Bredesen DE, Rao RV, Mehlen P: **Cell death in the nervous system.** *Nature* 2006, **443**:796-802.
19. Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST, Ganguli M: **Incidence of Alzheimer's disease in a rural community in India. The Indo-US study.** *Neurology* 2001, **57**:985-989.
20. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: **The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse.** *J Neurosci* 2001, **21**:8370-8377.
21. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hyland LM, Wexner SD, Giardiello FM: **Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.** *Clin Gastroenterol Hepatol* 2006, **4**:1035-1038.
22. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y: **Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.** *Clin Gastroenterol Hepatol* 2006, **4**:1502-1506.
23. Basu NK, Kole L, Kubota S, Owens IS: **Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin.** *Drug Metab Dispos* 2004, **32**:768-773.
24. Eaton EA, Walle UK, Lewis AJ, Hudson T, Wilson AA, Walle T: **Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention.** *Drug Metab Dispos* 1996, **24**:232-237.
25. Thapliyal R, Maru GB: **Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo.** *Food Chem Toxicol* 2001, **39**:541-547.
26. Zhang W, Tan TM, Lim LY: **Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celirolol and midazolam in rats.** *Drug Metab Dispos* 2007, **35**:110-115.
27. Narasimhan S: **Control of glycoprotein synthesis. UDP-GlcNAc:glycopeptide beta 4-N-acetylglucosaminyltransferase III, an enzyme in hen oviduct which adds GlcNAc in beta 1-4 linkage to the beta-linked mannose of the trimannosyl core of N-glycosyl oligosaccharides.** *J Biol Chem* 1982, **257**:10235-10242.
28. Nishikawa A, Ihara Y, Hatakeyama M, Kangawa K, Taniguchi N: **Purification, cDNA cloning, and expression of UDP-N-acetylglucosamine: beta-D-mannoside acetylglucosaminyltransferase III from rat kidney.** *J Biol Chem* 1992, **267**:18199-18204.
29. Taniguchi N, Miyoshi E, Ko JH, Ikeda Y, Ihara Y: **Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism.** *Biochim Biophys Acta* 1999, **1455**:287-300.
30. Shigeta M, Shibukawa Y, Ihara H, Miyoshi E, Taniguchi N, Gu J: **Beta1,4-N-acetylglucosaminyltransferase III potentiates beta1 integrin-mediated neuritogenesis induced by serum deprivation in Neuro2a cells.** *Glycobiology* 2006, **16**:564-571.
31. Ihara Y, Nishikawa A, Tohma T, Soejima H, Niikawa N, Taniguchi N: **cDNA cloning, expression, and chromosomal localization of human N-acetylglucosaminyltransferase III (GnT-III).** *J Biochem (Tokyo)* 1993, **113**:692-698.
32. Shibukawa Y, Takahashi M, Laffont I, Honke K, Taniguchi N: **Down-regulation of hydrogen peroxide-induced PKC delta activation in N-acetylglucosaminyltransferase III-transfected HeLaS3 cells.** *J Biol Chem* 2003, **278**:3197-3203.
33. Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, Legaspi A, Liu PT, Cole ST, Godowski PJ, Maeda Y, Sarno EN, Norgard MV, Brennan PJ, Akira S, Rea TH, Modlin RL: **Activation and regulation of Toll-like receptors 2 and 1 in human leprosy.** *Nat Med* 2003, **9**:525-532.
34. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ: **Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model.** *J Neurochem* 2007, **102**:1095-1104.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

